|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o BrainCells Inc., of San Diego, in-licensed a clinical-stage compound that it plans to develop for central nervous system diseases such as mood disorders from Mitsubishi Pharma Corp., of Osaka, Japan. BrainCells expects to begin development and initiate additional Phase II trials of the compound, BCI-540, next year. Mitsubishi had decided to halt the product's development in another indication, but BrainCells identified the new uses after applying its technology in the area of neurogenesis, the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. Financial terms were not disclosed.
o Caliper Life Sciences ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|